Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)

NCT06710847 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT06710847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06710847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 First-Time-in-Human, Open-label, Multicenter, Dose Escalation and Expansion Study of the Oral DNA Helicase Werner Inhibitor (WRNi) GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Adult Participants With Mismatch Repair-deficient (dMMR) or Microsatellite Instability-High (MSI-H) Solid Tumors (SYLVER)
Lead sponsor
GlaxoSmithKline
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 13, 2024
Completion date
June 22, 2026
Enrollment
14 (actual)
Sites
22

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, endometrial cancer, neoplasms, colorectal, rectal cancer, solid tumor